Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Emma Breault(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Kenneth C. Anderson(Dana-Farber Cancer Institute), Natalie Drummy(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Paul G. Richardson(Harvard University), Rinat Rotem‐Yehudar(Tel Aviv University), Nikhil C. Munshi(Dana-Farber Cancer Institute), Carol Delaney(Beth Israel Deaconess Medical Center), Michael Schickler(CureTech (Israel)), Jacob P. Laubach(Harvard University), Jamie Mortellite(Beth Israel Deaconess Medical Center), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Jacob M. Rowe(Technion – Israel Institute of Technology), Baldev Vasir(Beth Israel Deaconess Medical Center), Katharine Conway(Beth Israel Deaconess Medical Center), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Irit Avivi(Tel Aviv Sourasky Medical Center), Judith Wagoner(Beth Israel Deaconess Medical Center), Nancy Giallombardo(Beth Israel Deaconess Medical Center), Lina Bisharat(Beth Israel Deaconess Medical Center), Tami Katz(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), Vicki Held(Rambam Health Care Campus), James D. Levine(Beth Israel Deaconess Medical Center), Poorvi Somaiya(Beth Israel Deaconess Medical Center)
Cited by 7
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k